RMIT scientists in Melbourne have led an international collaboration that potentially unlocks better treatment of viral diseases, including the flu and common cold.
The results were published in the prestigious scientific and medical journal Nature Communications.
Each year the flu virus sends 13,500 Australians to hospital and causes more than 3000 deaths among those aged over 50. The global burden is also staggering, with more than 5 million cases of infection annually with up to 10 per cent resulting in death.
The RMIT senior authors, Dr Stavros Selemidis (ARC Future Fellow) and Dr Eunice To (first author), collaborated with Professor Doug Brooks from University South Australia, Professor John O’Leary from Trinity College Dublin, Monash University’s Professor Christopher Porter, and other scientists and clinicians to investigate how viruses cause disease in humans.
The researchers discovered that a 1.5 billion-year-old cell biological process found in plants, fungi and mammals enhances viral disease in mice and highly likely also in humans. They identified a protein, Nox2 oxidase, that is activated by viruses, including influenza, rhinovirus (the common cold), dengue and HIV.
Once activated, Nox2 oxidase suppresses the body’s key antiviral reaction and its ability to fight and clear the viral infection, which in turn results in a stronger or more virulent disease in mice.
The study also investigated a new prototype drug to treat these debilitating viral diseases.
The researchers found that the Nox2 oxidase protein activated by the viruses is located in a cell compartment called endosomes. They carefully modified a chemical that inhibits or restrains the activity of Nox2 oxidase.
Their customised drug was found to be very effective at suppressing disease caused by influenza infection.
Selemidis, head of the Oxidant and Inflammation Biology Group within the Chronic Infectious and Inflammatory Diseases program at RMIT, said: “Current treatment strategies are limited as they specifically target circulating viruses and have either unknown or very little effect against new viruses that enter the human population.
“We have identified a protein of the immune system that contributes to the disease caused by flu viruses irrespective of their strain.
“We also developed a novel drug delivery system to target this protein, which drastically alleviated the burden of viral disease.
“The strength of this work is the multidisciplinary approach taken and the degree of collaboration. It includes researchers and clinicians from eight universities across Australia, the United States and Ireland.
“This work attracted considerable interest at the NADPH Oxidase GORDON conference in the USA last year.”
To said: “This work identifies a treatment strategy that has the potential to alleviate the symptoms caused by some of the most devastating viruses worldwide, including the flu.”
The Latest on: Viral diseases
Rare infectious diseases are rising at an 'alarming' rate in Seattle's homeless population, concerning health officials
on March 17, 2018 at 1:42 am
King County public health officials are becoming increasingly concerned about a variety of outbreaks of serious infectious diseases among people who are homeless. Seattle-King County Public Health is investigating outbreaks of Group A Streptococcus ... […]
Infectious diseases on the rise as homeless population grows
on March 16, 2018 at 5:02 pm
SEATTLE – They`re diseases that you`ve never heard of, Shigella and Group A Strep. But they are spreading at alarming rates among people without homes in King County. Group Strep A can lead to cases of flesh-eating bacteria. Cases at Harborview Medical ... […]
Climate change spurs proliferation of disease-bearing insects, increases exposure to viral infections
on March 16, 2018 at 9:44 am
Scientists at the Joint Research Centre, the European Commission's science and knowledge service, find that global warming has allowed disease-bearing insects to proliferate, increasing exposure to viral infections. Spurred on by climate change ... […]
Seattle Infectious-Disease Outbreaks Cause Concern
on March 16, 2018 at 6:17 am
SEATTLE (AP) — Public health officials are becoming increasingly concerned about a variety of outbreaks of serious infectious diseases among people who are homeless in Seattle and throughout King County. The Seattle Times reports Seattle-King County ... […]
Global nucleic acid amplification testing market expected to be driven by increasing prevalence of infectious diseases
on March 15, 2018 at 12:05 am
Mar 15, 2018 (marketresearch.biz via COMTEX) -- Nucleic acid amplification testing tests is extensively for screening and diagnosis of a wide range of infectious diseases as it detects the presence of viral DNAs or RNAs in blood samples of the patients. […]
AI could help fight the spread infectious disease around the world
on March 14, 2018 at 7:10 am
Communicable diseases represent a critical challenge for resource-strapped public health infrastructures worldwide. As evidenced by the outbreaks of severe acute respiratory syndrome (SARS) in 2003, influenza A H1N1 (or “swine flu”) in 2009, Ebola and ... […]
VIDEO: Rapid entry HIV program reduces time to viral suppression in vulnerable populations
on March 14, 2018 at 3:09 am
BOSTON — Jonathan Colasanti, MD, MSPH, assistant professor of medicine at Emory University School of Medicine and associate medical director of the Grady Health Center Infectious Disease Program, reviews a study on the effectiveness of a rapid entry ... […]
Predicting infectious disease epidemics, probing gene regulatory networks with memory functions, explaining microbial growth/yield trade-offs
on March 13, 2018 at 11:17 am
Public health agencies such as the US Centers for Disease Control and Prevention would like to have as much information as possible when planning interventions intended to reduce and prevent the spread of infectious disease. For instance, accurate and ... […]
Summit’s Infectious Diseases Technology Platform Yields Novel Antibiotics with Potential in Global Fight Against Gonorrhoea
on March 13, 2018 at 4:19 am
Oxford, UK, and Cambridge, MA, US, 13 March 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces the discovery of a series of antibiotic compounds that kill gonorrhoea bacteria via new mechanisms of action. There is a pressing need for ... […]
via Google News and Bing News